NEWS

Can-Fite reports on progress with its Namodenoson NASH program

  • 2020.12.18
  • NEWS RELEASE

Can-Fite (Israel) reports on 14 December, 2020, on progress with its Namodenoson NASH program.

 

For detailed information, see the below URL.

https://www.cytodyn.com/newsroom/press-releases/detail/489/cytodyn-announces-first-patient-enrolled-in-phase-2-trial

 

Namodenoson is a A3 adensine receptor agonist. 

The compound used the STAM™ mouse model for non-clinical studies, and data showing the improvement of steatohepatitis in the STAM™ mouse model.

 

For detailed information, see the below URL.

https://www.spandidos-publications.com/ijmm/44/6/2256